CN104862267B - 适应于无血清培养和悬浮培养的mdck来源的细胞系与利用该细胞制备疫苗病毒的方法 - Google Patents
适应于无血清培养和悬浮培养的mdck来源的细胞系与利用该细胞制备疫苗病毒的方法 Download PDFInfo
- Publication number
- CN104862267B CN104862267B CN201510201640.3A CN201510201640A CN104862267B CN 104862267 B CN104862267 B CN 104862267B CN 201510201640 A CN201510201640 A CN 201510201640A CN 104862267 B CN104862267 B CN 104862267B
- Authority
- CN
- China
- Prior art keywords
- mdck
- cell
- source
- culture
- virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000002966 serum Anatomy 0.000 title claims abstract description 40
- 241000700605 Viruses Species 0.000 title claims abstract description 30
- 238000000034 method Methods 0.000 title claims abstract description 27
- 229960005486 vaccine Drugs 0.000 title claims abstract description 18
- 238000002360 preparation method Methods 0.000 claims abstract description 21
- 238000004321 preservation Methods 0.000 claims abstract description 5
- 210000003734 kidney Anatomy 0.000 claims abstract description 4
- 241000712461 unidentified influenza virus Species 0.000 claims description 18
- 239000001963 growth medium Substances 0.000 claims description 15
- 239000012679 serum free medium Substances 0.000 claims description 14
- 238000004113 cell culture Methods 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 239000002574 poison Substances 0.000 claims description 4
- 231100000614 poison Toxicity 0.000 claims description 4
- 241000709687 Coxsackievirus Species 0.000 claims description 3
- 241000991587 Enterovirus C Species 0.000 claims description 3
- 241000701074 Human alphaherpesvirus 2 Species 0.000 claims description 3
- 241000712079 Measles morbillivirus Species 0.000 claims description 3
- 241000711386 Mumps virus Species 0.000 claims description 3
- 241000711798 Rabies lyssavirus Species 0.000 claims description 3
- 241000710799 Rubella virus Species 0.000 claims description 3
- 241000700618 Vaccinia virus Species 0.000 claims description 3
- 241000710772 Yellow fever virus Species 0.000 claims description 3
- 206010022000 influenza Diseases 0.000 claims description 3
- 239000002609 medium Substances 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- 241000701161 unidentified adenovirus Species 0.000 claims description 3
- 229940051021 yellow-fever virus Drugs 0.000 claims description 3
- 241000700588 Human alphaherpesvirus 1 Species 0.000 claims description 2
- 241000712902 Lassa mammarenavirus Species 0.000 claims description 2
- 241000125945 Protoparvovirus Species 0.000 claims description 2
- 241000702263 Reovirus sp. Species 0.000 claims description 2
- 241000725643 Respiratory syncytial virus Species 0.000 claims description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 239000001301 oxygen Substances 0.000 claims description 2
- 238000009395 breeding Methods 0.000 claims 1
- 230000001488 breeding effect Effects 0.000 claims 1
- 206010014599 encephalitis Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 148
- 241000699666 Mus <mouse, genus> Species 0.000 description 16
- 238000012360 testing method Methods 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 230000010261 cell growth Effects 0.000 description 7
- 230000012010 growth Effects 0.000 description 7
- 239000000243 solution Substances 0.000 description 6
- 230000003612 virological effect Effects 0.000 description 5
- 230000003321 amplification Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000011081 inoculation Methods 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 102000002322 Egg Proteins Human genes 0.000 description 3
- 108010000912 Egg Proteins Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000004114 suspension culture Methods 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 2
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 230000036952 cancer formation Effects 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 230000005779 cell damage Effects 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 230000035931 haemagglutination Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 229960003971 influenza vaccine Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000000394 mitotic effect Effects 0.000 description 2
- 238000011580 nude mouse model Methods 0.000 description 2
- 210000004681 ovum Anatomy 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000000197 pyrolysis Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 101710186708 Agglutinin Proteins 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 101710146024 Horcolin Proteins 0.000 description 1
- 241000710842 Japanese encephalitis virus Species 0.000 description 1
- 241000710843 Japanese encephalitis virus group Species 0.000 description 1
- 101710189395 Lectin Proteins 0.000 description 1
- 241001480512 Mammalian orthoreovirus 3 Species 0.000 description 1
- 101710179758 Mannose-specific lectin Proteins 0.000 description 1
- 101710150763 Mannose-specific lectin 1 Proteins 0.000 description 1
- 101710150745 Mannose-specific lectin 2 Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000029797 Prion Human genes 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- 240000000111 Saccharum officinarum Species 0.000 description 1
- 235000007201 Saccharum officinarum Nutrition 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 239000000910 agglutinin Substances 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 231100000588 tumorigenic Toxicity 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 229960004854 viral vaccine Drugs 0.000 description 1
- 230000005727 virus proliferation Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0684—Cells of the urinary tract or kidneys
- C12N5/0686—Kidney cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16151—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16151—Methods of production or purification of viral material
- C12N2760/16152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16171—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16251—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16251—Methods of production or purification of viral material
- C12N2760/16252—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16271—Demonstrated in vivo effect
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
实验组 | 细胞系 | 接种抗原的量 | HI滴度 |
1 | MDCK Sky1023 | 15μg/鼠 | 80 |
2 | MDCK Sky10234 | 15μg/鼠 | 160 |
3 | MDCK Sky10234 | 7.5μg/鼠 | 160 |
4 | MDCK Sky3851 | 15μg/鼠 | 80 |
5 | MDCK Sky3851 | 7.5μg/鼠 | 80 |
6 | 参考疫苗 | 320 |
Claims (8)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KRPCT/KR2010/006041 | 2010-09-06 | ||
PCT/KR2010/006041 WO2012033236A1 (ko) | 2010-09-06 | 2010-09-06 | 무혈청 배양 및 부유 배양에 적응된 mdck 세포주 및 상기 세포를 사용하여 백신용 바이러스를 제조하는 방법 |
KR10-2011-0085902 | 2011-08-26 | ||
KR1020110085902A KR20120024464A (ko) | 2010-09-06 | 2011-08-26 | 무혈청 배양 및 부유 배양에 적응된 mdck 세포주 및 상기 세포를 사용하여 백신용 바이러스를 제조하는 방법 |
CN2011800429238A CN103154238A (zh) | 2010-09-06 | 2011-09-06 | 适应于无血清培养和悬浮培养的mdck来源的细胞系与利用该细胞制备疫苗病毒的方法 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2011800429238A Division CN103154238A (zh) | 2010-09-06 | 2011-09-06 | 适应于无血清培养和悬浮培养的mdck来源的细胞系与利用该细胞制备疫苗病毒的方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104862267A CN104862267A (zh) | 2015-08-26 |
CN104862267B true CN104862267B (zh) | 2019-07-12 |
Family
ID=45810820
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2011800429238A Pending CN103154238A (zh) | 2010-09-06 | 2011-09-06 | 适应于无血清培养和悬浮培养的mdck来源的细胞系与利用该细胞制备疫苗病毒的方法 |
CN201510201640.3A Active CN104862267B (zh) | 2010-09-06 | 2011-09-06 | 适应于无血清培养和悬浮培养的mdck来源的细胞系与利用该细胞制备疫苗病毒的方法 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2011800429238A Pending CN103154238A (zh) | 2010-09-06 | 2011-09-06 | 适应于无血清培养和悬浮培养的mdck来源的细胞系与利用该细胞制备疫苗病毒的方法 |
Country Status (19)
Country | Link |
---|---|
US (2) | US20130183741A1 (zh) |
EP (1) | EP2614140B8 (zh) |
JP (1) | JP6067560B2 (zh) |
KR (2) | KR20120024464A (zh) |
CN (2) | CN103154238A (zh) |
AU (1) | AU2011299761B2 (zh) |
BR (1) | BR112013005298A2 (zh) |
CY (1) | CY1120911T1 (zh) |
DK (1) | DK2614140T3 (zh) |
ES (1) | ES2695044T3 (zh) |
HR (1) | HRP20181422T1 (zh) |
HU (1) | HUE040534T2 (zh) |
LT (1) | LT2614140T (zh) |
PL (1) | PL2614140T3 (zh) |
PT (1) | PT2614140T (zh) |
RS (1) | RS57656B1 (zh) |
SI (1) | SI2614140T1 (zh) |
TR (1) | TR201815631T4 (zh) |
WO (2) | WO2012033236A1 (zh) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2647985C (en) | 2006-03-31 | 2014-12-30 | Warf-Wisconsin Alumni Research Foundation | High titer recombinant influenza viruses for vaccines |
US9474798B2 (en) | 2007-06-18 | 2016-10-25 | Wisconsin Alumni Research Foundation | Influenza M2 protein mutant viruses as live influenza attenuated vaccines |
JP2013507990A (ja) | 2009-10-26 | 2013-03-07 | ダブリュエーアールエフ−ウィスコンシン アラムナイ リサーチ ファウンデーション | ベロ細胞において増強された複製を有する高力価の組換えインフルエンザウイルス |
US10130697B2 (en) | 2010-03-23 | 2018-11-20 | Wisconsin Alumni Research Foundation (Warf) | Vaccines comprising mutant attenuated influenza viruses |
WO2012033236A1 (ko) * | 2010-09-06 | 2012-03-15 | 에스케이케미칼 주식회사 | 무혈청 배양 및 부유 배양에 적응된 mdck 세포주 및 상기 세포를 사용하여 백신용 바이러스를 제조하는 방법 |
JP6152535B2 (ja) * | 2012-04-16 | 2017-06-28 | 公益財団法人ヒューマンサイエンス振興財団 | 細胞培養組成物及びインフルエンザウイルスの生産方法 |
CN104059873B (zh) * | 2013-03-20 | 2016-09-28 | 上海生物制品研究所有限责任公司 | 用于扩增流感病毒的非致瘤性mdck细胞系及其筛选方法 |
KR101370512B1 (ko) | 2013-06-07 | 2014-03-06 | 재단법인 목암생명공학연구소 | 무단백 배지에서 부유 배양되는 mdck 유래 세포주 및 상기 세포주를 이용하여 바이러스를 증식시키는 방법 |
AU2014290203B2 (en) | 2013-07-15 | 2020-12-24 | Wisconsin Alumni Research Foundation | High titer recombinant influenza viruses with enhanced replication in MDCK or vero cells or eggs |
CN104726392B (zh) * | 2013-12-18 | 2018-09-28 | 普莱柯生物工程股份有限公司 | 一种制备无血清培养的悬浮哺乳动物细胞系的方法、及其制备的细胞系和应用 |
WO2015196150A2 (en) | 2014-06-20 | 2015-12-23 | Wisconsin Alumni Research Foundation (Warf) | Mutations that confer genetic stability to additional genes in influenza viruses |
US10633422B2 (en) | 2015-06-01 | 2020-04-28 | Wisconsin Alumni Research Foundation (Warf) | Influenza virus replication by inhibiting microRNA lec7C binding to influenza viral cRNA and mRNA |
WO2017007839A1 (en) | 2015-07-06 | 2017-01-12 | Wisconsin Alumni Research Foundation (Warf) | Improved influenza virus replication for vaccine development |
TWI781915B (zh) | 2015-10-30 | 2022-11-01 | 財團法人國家衛生研究院 | 用於疫苗製備之於無血清、化學性界定培養基中之mdck懸浮細胞株 |
CN109477074B (zh) | 2016-02-19 | 2023-01-24 | 威斯康星旧生研究基金会 | 用于疫苗开发的改进的乙型流感病毒复制 |
CN107460156B (zh) * | 2016-06-03 | 2022-03-11 | 兆丰华生物科技(南京)有限公司北京生物医药科技中心 | 无血清全悬浮mdck细胞株及其在生产流感病毒中的应用 |
CN105861422B (zh) * | 2016-06-24 | 2019-05-24 | 肇庆大华农生物药品有限公司 | 一种适应无血清全悬浮培养的mdck细胞系的制备方法及通过该制备方法获得的mdck细胞系 |
EP3299454A1 (en) * | 2016-09-21 | 2018-03-28 | Deutsches Krebsforschungszentrum | Optimized method for large scale production of parvovirus h-1 in an essentially serum-free medium |
CN106801031A (zh) * | 2017-01-22 | 2017-06-06 | 西北民族大学 | 无成瘤性mdck细胞克隆株 |
CN106884003A (zh) * | 2017-01-22 | 2017-06-23 | 西北民族大学 | 无成瘤性mdck细胞克隆株 |
KR101831284B1 (ko) * | 2017-06-26 | 2018-02-22 | 에스케이케미칼 주식회사 | 무혈청 배지에서 부유배양 되는 Vero 세포주 및 상기 세포를 사용하여 백신용 바이러스를 제조하는 방법 |
KR102453351B1 (ko) * | 2017-07-05 | 2022-10-07 | 에스케이바이오사이언스(주) | 인플루엔자 백신용 바이러스 씨드 스톡의 제조 방법 |
CN108277199B (zh) * | 2018-01-17 | 2021-06-25 | 武汉生物制品研究所有限责任公司 | 广谱低致瘤性mdck细胞系及其应用 |
WO2020167432A2 (en) | 2019-01-23 | 2020-08-20 | Yoshihiro Kawaoka | Mutations that confer genetic stability to additional genes in influenza viruses |
JP2022522112A (ja) | 2019-02-08 | 2022-04-14 | ウィスコンシン アルムニ リサーチ ファンデイション | ヒト化細胞系 |
CN109852580A (zh) * | 2019-03-27 | 2019-06-07 | 西北民族大学 | 无血清悬浮培养型mdck细胞株及其应用 |
CN109852579A (zh) * | 2019-03-27 | 2019-06-07 | 西北民族大学 | 无血清悬浮培养型mdck细胞株及其应用 |
WO2020223699A1 (en) | 2019-05-01 | 2020-11-05 | Wisconsin Alumni Research Foundation (Warf) | Improved influenza virus replication for vaccine development |
EP4022046A2 (en) | 2019-08-27 | 2022-07-06 | Wisconsin Alumni Research Foundation (WARF) | Recombinant influenza viruses with stabilized ha for replication in eggs |
CN110669722A (zh) * | 2019-10-23 | 2020-01-10 | 长春生物制品研究所有限责任公司 | 一种用于mdck细胞的无血清全悬浮驯化方法 |
JP2023524015A (ja) | 2020-04-29 | 2023-06-08 | エスケー バイオサイエンス カンパニー リミテッド | 使い捨て培養工程システムを用いたインフルエンザウイルス生産方法及びインフルエンザウイルス抗原精製条件の迅速確認試験 |
KR102444684B1 (ko) * | 2020-04-29 | 2022-09-16 | 에스케이바이오사이언스(주) | 일회용 배양 공정 시스템을 이용한 인플루엔자 바이러스 생산 방법 |
CN112195148B (zh) * | 2020-08-17 | 2023-01-03 | 上海生物制品研究所有限责任公司 | 无血清悬浮适应的mdck细胞及其在制备流感病毒疫苗中的应用 |
CN112410305A (zh) * | 2020-11-26 | 2021-02-26 | 中国医学科学院病原生物学研究所 | 一种高产的流感病毒制备体系及制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6825036B2 (en) * | 2000-03-03 | 2004-11-30 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Cell usable in serum-free culture and suspension culture and process for producing virus for vaccine by using the cell |
CN101189326A (zh) * | 2004-12-23 | 2008-05-28 | 米迪缪尼疫苗股份有限公司 | 用于病毒增殖的非致瘤性mdck细胞系 |
WO2010036760A1 (en) * | 2008-09-24 | 2010-04-01 | Medimmune, Llc | Methods for cultivating cells, propagating and purifying viruses |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10144906B4 (de) * | 2001-09-12 | 2013-11-28 | Novartis Vaccines And Diagnostics Gmbh | Verfahren zur großtechnischen Herstellung von Impfstoffen |
EP2497495B3 (en) * | 2006-09-11 | 2021-02-17 | Seqirus UK Limited | Making influenza virus vaccines without using eggs |
WO2012033236A1 (ko) * | 2010-09-06 | 2012-03-15 | 에스케이케미칼 주식회사 | 무혈청 배양 및 부유 배양에 적응된 mdck 세포주 및 상기 세포를 사용하여 백신용 바이러스를 제조하는 방법 |
-
2010
- 2010-09-06 WO PCT/KR2010/006041 patent/WO2012033236A1/ko active Application Filing
-
2011
- 2011-08-26 KR KR1020110085902A patent/KR20120024464A/ko not_active Application Discontinuation
- 2011-09-06 TR TR2018/15631T patent/TR201815631T4/tr unknown
- 2011-09-06 PT PT11823761T patent/PT2614140T/pt unknown
- 2011-09-06 BR BR112013005298-8A patent/BR112013005298A2/pt not_active Application Discontinuation
- 2011-09-06 LT LTEP11823761.9T patent/LT2614140T/lt unknown
- 2011-09-06 SI SI201131565T patent/SI2614140T1/sl unknown
- 2011-09-06 EP EP11823761.9A patent/EP2614140B8/en active Active
- 2011-09-06 CN CN2011800429238A patent/CN103154238A/zh active Pending
- 2011-09-06 HU HUE11823761A patent/HUE040534T2/hu unknown
- 2011-09-06 RS RS20181032A patent/RS57656B1/sr unknown
- 2011-09-06 CN CN201510201640.3A patent/CN104862267B/zh active Active
- 2011-09-06 DK DK11823761.9T patent/DK2614140T3/en active
- 2011-09-06 WO PCT/KR2011/006589 patent/WO2012033328A2/en active Application Filing
- 2011-09-06 ES ES11823761.9T patent/ES2695044T3/es active Active
- 2011-09-06 AU AU2011299761A patent/AU2011299761B2/en active Active
- 2011-09-06 PL PL11823761T patent/PL2614140T3/pl unknown
- 2011-09-06 JP JP2013527024A patent/JP6067560B2/ja active Active
-
2013
- 2013-03-05 US US13/785,757 patent/US20130183741A1/en not_active Abandoned
-
2015
- 2015-05-07 KR KR1020150063976A patent/KR101577745B1/ko active IP Right Grant
- 2015-05-13 US US14/711,489 patent/US9447383B2/en active Active
-
2018
- 2018-09-05 HR HRP20181422TT patent/HRP20181422T1/hr unknown
- 2018-10-16 CY CY181101058T patent/CY1120911T1/el unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6825036B2 (en) * | 2000-03-03 | 2004-11-30 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Cell usable in serum-free culture and suspension culture and process for producing virus for vaccine by using the cell |
CN101189326A (zh) * | 2004-12-23 | 2008-05-28 | 米迪缪尼疫苗股份有限公司 | 用于病毒增殖的非致瘤性mdck细胞系 |
WO2010036760A1 (en) * | 2008-09-24 | 2010-04-01 | Medimmune, Llc | Methods for cultivating cells, propagating and purifying viruses |
Non-Patent Citations (2)
Title |
---|
Conversion of MDCK cell line to suspension culture by transfecting with human siat7e gene and its application for influenza virus production;Chia Chua等;《PNAS》;20090901;第106卷(第35期);第14802-14807页 |
Production of Cell Culture (MDCK) Derived Live Attenuated Influenza Vaccine (LAIV) in a Fully Disposable Platform Process;Meena George等;《BIOTECHNOLOGY AND BIOENGINEERING》;20100815;第106卷(第6期);第906-917页 |
Also Published As
Publication number | Publication date |
---|---|
AU2011299761A1 (en) | 2013-03-21 |
PL2614140T3 (pl) | 2019-02-28 |
US20130183741A1 (en) | 2013-07-18 |
WO2012033236A1 (ko) | 2012-03-15 |
EP2614140A4 (en) | 2014-03-05 |
EP2614140B8 (en) | 2018-10-17 |
HUE040534T2 (hu) | 2019-03-28 |
LT2614140T (lt) | 2018-10-25 |
EP2614140B1 (en) | 2018-08-08 |
CY1120911T1 (el) | 2019-12-11 |
HRP20181422T1 (hr) | 2018-10-19 |
EP2614140A2 (en) | 2013-07-17 |
PT2614140T (pt) | 2018-11-22 |
US9447383B2 (en) | 2016-09-20 |
DK2614140T3 (en) | 2018-10-22 |
WO2012033328A2 (en) | 2012-03-15 |
CN104862267A (zh) | 2015-08-26 |
CN103154238A (zh) | 2013-06-12 |
KR20120024464A (ko) | 2012-03-14 |
WO2012033328A3 (en) | 2012-06-28 |
AU2011299761B2 (en) | 2017-01-05 |
KR20150056519A (ko) | 2015-05-26 |
US20150247128A1 (en) | 2015-09-03 |
ES2695044T3 (es) | 2018-12-28 |
TR201815631T4 (tr) | 2018-11-21 |
KR101577745B1 (ko) | 2015-12-16 |
RS57656B1 (sr) | 2018-11-30 |
BR112013005298A2 (pt) | 2020-01-07 |
JP6067560B2 (ja) | 2017-01-25 |
JP2013540431A (ja) | 2013-11-07 |
SI2614140T1 (sl) | 2018-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104862267B (zh) | 适应于无血清培养和悬浮培养的mdck来源的细胞系与利用该细胞制备疫苗病毒的方法 | |
CA2250078C (en) | Processes for the replication of influenza viruses in cell culture, and the influenza viruses obtainable by the process | |
JP4243349B2 (ja) | インフルエンザウイルスの複製のための動物細胞および方法 | |
CN110093307A (zh) | 适应无血清悬浮培养的bhk-21-sc细胞株和用该细胞株制备疫苗抗原的方法 | |
CN104232594B (zh) | 重组类禽型h1n1流感病毒灭活疫苗株(js40/pr8)及其制备方法和应用 | |
CN107460156A (zh) | 无血清全悬浮mdck细胞株及其在生产流感病毒中的应用 | |
CN107904215A (zh) | 一种禽流感病毒的全悬浮培养方法 | |
CN104001167A (zh) | 全悬浮培养细胞制造禽流感灭活疫苗工艺及产品 | |
CN102133398A (zh) | 应用生物反应器工业化生产动物流感疫苗的方法 | |
CN106119212A (zh) | 禽腺病毒毒株、灭活疫苗及制备方法 | |
JP6110357B2 (ja) | イヌ腎細胞の浮遊培養物においてウイルスを複製する方法 | |
CN105664150A (zh) | 一种鸡新城疫病毒、禽流感病毒和禽腺病毒三联灭活疫苗 | |
CN105121634B (zh) | 具有提高的病毒生产能力的细胞系及其生产方法 | |
CN104726409B (zh) | 一种永生化的鸭胚肝细胞系的制备方法和应用 | |
CN108159412A (zh) | 一种生产细胞源鸡新城疫、禽流感二联灭活疫苗的方法及其产品 | |
CN108261543B (zh) | 传代细胞源nd、ib、ai三联灭活疫苗的制备方法及其应用 | |
CN102858961A (zh) | 新方法 | |
CN106085947B (zh) | Mdck克隆细胞株及其应用 | |
CN107603942B (zh) | 用于流感疫苗生产的mdck细胞株 | |
RU2330885C2 (ru) | Способ получения живой культуральной вакцины против вируса гриппа | |
CA2250714C (en) | Animal cells and processes for the replication of influenza viruses | |
TW201040257A (en) | Vaccine produced with suspension microcarrier cell culturing system and method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
EXSB | Decision made by sipo to initiate substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information |
Address after: Gyeonggi Do, South Korea Applicant after: SK discovery Corp. Address before: Gyeonggi Do, South Korea Applicant before: SK CHEMICALS Co.,Ltd. |
|
CB02 | Change of applicant information | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20180919 Address after: Gyeonggi Do, South Korea Applicant after: SK Chemical Co.,Ltd. Address before: Gyeonggi Do, South Korea Applicant before: SK discovery Corp. |
|
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20181019 Address after: Gyeonggi Do, South Korea Applicant after: SK BIOSCIENCE Co.,Ltd. Address before: Gyeonggi Do, South Korea Applicant before: SK Chemical Co.,Ltd. |
|
TA01 | Transfer of patent application right | ||
GR01 | Patent grant | ||
GR01 | Patent grant |